Abstract: A radioactive source removing and introducing tooling includes a first support frame, a shield door disposed on the first support frame, a shield cover located on the shield door, and a first pull rod device. The shield door includes a movable first shield block. The shield cover is able to be separated from the shield door, and the shield cover includes one opening and one accommodation space. The first pull rod device includes a pull rod and a first connection portion disposed on the pull rod, and the pull rod is able to extend into the shield cover and drive the first connection portion to move inside the accommodation space of the shield cover.

Abstract: A positioning stud for radioactive therapy includes a stud rod, a stud tip, and an insulating component. The insulating component is connected between the stud rod and the stud tip, and is used to prevent contact between the stud rod and the stud tip.

Abstract: A method of processing a workpiece is disclosed, where the interior surfaces of the plasma chamber are first coated using a conditioning gas that contains the desired dopant species. A working gas, which does not contain the desired dopant species, is then introduced and energized to form a plasma. This plasma is used to sputter the desired dopant species from the interior surfaces. This dopant species is deposited on the workpiece. A subsequent implant process may then be performed to implant the dopant into the workpiece. The implant process may include a thermal treatment, a knock in mechanism, or both.

Abstract: Various examples are described for defining automations for client devices enrolled with a management service. A computing environment can cause one or more user interfaces to be shown in a display of an administrator device that include at least one field for receiving a conditional statement to generate an automation associated with client devices enrolled with the management service. The computing environment can validate the conditional statement based on validation criteria and, in an instance in which the conditional statement has been validated, execute a query to determine a number of the client devices affected by the conditional statement. As a result of the query, the computing environment can display information associated with a number of the client devices affected by the conditional statement.

Abstract: The present invention relates to an apparatus for assessing medical device quality. It is described to provide (210) at least one report associated with at least one medical image acquired by a medical device, wherein a report is associated with a corresponding medical image. The at least one report is analyzed and at least one image quality parameter is generated (220), wherein an image quality parameter is associated with a 5 corresponding report. The at least one image quality parameter is assessed and generating alert information relating to the medical device is generated (230).

Abstract: The object of the present invention is to provide a polymer capable of being insolubilized at a low temperature in a short time, having a high hole injecting and transporting ability and a high durability, and a composition for organic electroluminescent element comprising the polymer. The polymer of the present invention comprises a specific crosslinkable group.

Abstract: A method of processing a workpiece is disclosed, where the interior surfaces of the plasma chamber are first coated using a conditioning gas that contains the desired dopant species. A working gas, which does not contain the desired dopant species, is then introduced and energized to form a plasma. This plasma is used to sputter the desired dopant species from the interior surfaces. This dopant species is deposited on the workpiece. A subsequent implant process may then be performed to implant the dopant into the workpiece. The implant process may include a thermal treatment, a knock in mechanism, or both.

Abstract: The present invention discloses a pipe material including the pipe body. Spacers are set inside the pipe body. The outer wall of the spacer is in close fit with the inner wall of the pipe body. In the present invention, the spacer set inside the pipe material can well support the pipe wall and better enhance the mechanical strength and anti-bending performance of the pipe. Due to the close fit between the outer wall of the spacer and the inner wall of the pipe body, the bonding between the spacer with certain thickness and the pipe body enhances its force in any direction and improves the stress performance of the pipe body. The interaction of multiple spacers ensures the local stability of the pipe body between spacers. The interaction between the spacer and the pipe wall ultimately improves various performances of the pipe, especially its anti-bending performance.

Abstract: The object of the present invention is to provide a polymer capable of being insolubilized at a low temperature in a short time, having a high hole injecting and transporting ability and a high durability, and a composition for organic electroluminescent element comprising the polymer. The polymer of the present invention comprises a specific crosslinkable group.

Abstract: The invention relates to an improved process for synthesizing N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide of the formula: (I) Compound (I) is currently in clinical trials for the treatment of myeloproliferative disorders, such as polycythaemia vera, thrombocythaemia and primary myelofibrosis.

Abstract: The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form.

Abstract: The invention relates to an improved process for synthesizing N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide of the formula: (I) Compound (I) is currently in clinical trials for the treatment of myeloproliferative disorders, such as polycythaemia vera, thrombocythaemia and primary myelofibrosis.

Abstract: The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form.

Abstract: Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.

Abstract: The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form.

Abstract: The present invention discloses a pipe material including the pipe body. Spacers are set inside the pipe body. The outer wall of the spacer is in close fit with the inner wall of the pipe body. In the present invention, the spacer set inside the pipe material can well support the pipe wall and better enhance the mechanical strength and anti-bending performance of the pipe. Due to the close fit between the outer wall of the spacer and the inner wall of the pipe body, the bonding between the spacer with certain thickness and the pipe body enhances its force in any direction and improves the stress performance of the pipe body. The interaction of multiple spacers ensures the local stability of the pipe body between spacers. The interaction between the spacer and the pipe wall ultimately improves various performances of the pipe, especially its anti-bending performance.

Abstract: A method and system for determining potential deadlock conditions in a target multi-threaded software application. The target application is first run in a virtual machine and the events within the application are recorded. The recorded events are replayed and analyzed to identify potential lock acquisition conflicts occurring between threads of the application. The potential lock acquisition conflicts are identified by analyzing the order in which resource locks are obtained and pairs of resources that have respective locks obtained in different orders are analyzed. These analyzed pairs are used to define a different order of events in the target application that, when the target application is re-run with the second order of events, may trigger a deadlock condition. The target application is then re-run with the different order of events in an attempt to trigger and then identify potential deadlock situations.

Abstract: Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.

Abstract: Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.

Abstract: The present disclosure generally relates to a crystalline form of methyl ((1S)-1-(((2S)-2-(5-(4?-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt. The present disclosure also generally relates to a pharmaceutical composition comprising a crystalline form, as well of methods of using a crystalline form in the treatment of Hepatitis C and methods for obtaining such crystalline form.